Synaffix BV

Biotechnology company with a platform technology for the development of more effective and better tolerated targeted cancer therapeutics.

Synaffix is a Netherlands-based biotech exclusively focused on continued advancement of a best-in-class antibody-drug conjugate (ADC) technology that results in safer and more effective ADCs, compared to marketed and emerging approaches. Synaffix’ vision is to become the preferred partner in the development of these complex biological therapeutics and realize the ambition, connect to cure. We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and MS Ventures the strategic corporate venture capital arm of Merck KGaA.